위암 치료제 시장 : 치료 분류별, 치료 라인별, 투여 경로별, 제형별, 치료법별, 유통 채널별 시장 예측(2026-2032년)

The Gastric Cancer Drugs Market is projected to grow by USD 6.63 billion at a CAGR of 6.34% by 2032.

Gastric cancer remains a high-burden oncology field, with GLOBOCAN 2022 estimating about 969,000 new stomach cancer cases and nearly 660,000 deaths worldwide. This disease burden sustains demand for gastric cancer drugs across chemotherapy, targeted therapy, immuno-oncology, anti-angiogenic therapy, and emerging biomarker-directed regimens.

The commercial landscape is shifting from one-size-fits-all cytotoxic treatment toward precision medicine. HER2, PD-L1 combined positive score, MSI-H/dMMR, EBV status, and CLDN18.2 testing increasingly shape first-line and later-line therapy selection, positioning gastric cancer therapeutics as a competitive market where clinical differentiation, companion diagnostics, treatment sequencing, and real-world outcomes are central to adoption.

Transformative Shifts in the Gastric Cancer Treatment Landscape

The most important shift in gastric cancer treatment is the movement of immunotherapy and targeted therapy into earlier lines of care. Checkpoint inhibitors have expanded treatment options for advanced gastric and gastroesophageal junction cancers, particularly in biomarker-defined populations, while HER2-directed therapy remains essential for HER2-positive disease and chemotherapy continues to serve as a backbone across multiple treatment settings.

Another transformative change is the rise of CLDN18.2 as a validated target, supported by regulatory approvals in major markets for eligible HER2-negative gastric and gastroesophageal junction adenocarcinoma. This expands the landscape beyond traditional HER2 and PD-1 strategies and increases the importance of broad biomarker testing at diagnosis, multidisciplinary treatment planning, and evidence-based sequencing of gastric cancer drugs.

Cumulative Impact of Artificial Intelligence on Gastric Cancer Drugs

Artificial intelligence is strengthening gastric cancer drug development by accelerating target discovery, clinical trial matching, patient stratification, digital pathology review, and imaging-based response assessment. AI-enabled pathology and radiomics can help identify biomarker expression patterns, tumor heterogeneity, immune microenvironment signals, and patients more likely to benefit from immunotherapy or targeted agents.

The cumulative impact is operational as well as scientific. AI can improve clinical trial feasibility, optimize site selection in high-incidence regions, support adverse event detection through real-world data analytics, and refine evidence generation after launch. For industry leaders, responsible AI adoption can shorten development cycles while improving evidence quality, reproducibility, and patient selection across gastric cancer therapeutics.

Key Regional Insights for Gastric Cancer Drugs

Asia-Pacific is the epidemiological center of gastric cancer drugs demand, driven by high incidence in China, Japan, South Korea, and parts of Southeast Asia. Publicly reported cancer burden data consistently show Eastern Asia as one of the highest-risk regions for stomach cancer, while national screening programs in Japan and South Korea support earlier detection and structured referral pathways. At the same time, large advanced-stage patient populations across the region sustain the need for systemic therapies, including chemotherapy, immune checkpoint inhibitors, HER2-directed therapy, anti-angiogenic agents, and CLDN18.2-targeted treatment.

North America demonstrates strong adoption of biomarker-led gastric cancer treatment due to mature oncology infrastructure, broad clinical trial participation, molecular testing availability, and guideline-driven care pathways. Europe similarly benefits from coordinated regulatory standards, established cancer networks, and reimbursement assessments that increasingly consider companion diagnostics, survival outcomes, toxicity profiles, and quality-of-life evidence. In Latin America, gastric cancer drug adoption is supported by rising oncology investment and growing private-sector access, although public reimbursement and molecular testing availability remain uneven across countries.

The Middle East is advancing through investment in specialized cancer centers, genomic medicine programs, and referral networks, creating opportunities for precision oncology drugs and companion diagnostic integration. Africa faces a more fragmented access environment, with late-stage diagnosis, limited pathology capacity, and affordability constraints influencing uptake of novel gastric cancer therapeutics. Across all regions, the strongest opportunities are linked to earlier diagnosis, scalable biomarker testing, equitable access models, and evidence that supports treatment value in real-world clinical practice.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are expanding through improving oncology infrastructure, rising diagnostic capacity, and broader access to systemic cancer treatment, although availability of biomarker testing and advanced gastric cancer drugs varies significantly across member countries. The GCC is investing in specialized cancer centers, digital health infrastructure, and genomic medicine initiatives, creating favorable conditions for premium targeted therapies, immuno-oncology regimens, and companion diagnostics in gastric cancer care.

The European Union benefits from centralized regulatory review, health technology assessment processes, and strong clinical guideline alignment, supporting consistent evidence standards across member states while still reflecting country-level reimbursement differences. BRICS countries represent a large clinical demand base, led by China and India in patient volume and by expanding oncology research capacity across the group. These markets are increasingly important for clinical trial recruitment, local manufacturing strategies, and access programs designed for high-burden cancer populations.

G7 markets remain key launch territories for innovative gastric cancer drugs because of advanced oncology systems, robust regulatory frameworks, precision medicine adoption, and high levels of specialist care access. NATO countries overlap with several high-income healthcare systems where oncology access, medicine supply resilience, and health security are strategic priorities. Across ASEAN, GCC, the European Union, BRICS, G7, and NATO, industry success depends on aligning evidence generation with local reimbursement expectations, diagnostic readiness, and national cancer-control priorities.

Key Country Insights in Major Gastric Cancer Drug Markets

The United States leads in rapid adoption of FDA-approved gastric cancer drugs, broad biomarker testing, and clinical trial activity, supported by guideline-based oncology practice and high availability of precision medicine infrastructure. Canada emphasizes evidence-based reimbursement, provincial access decisions, and equitable delivery of cancer medicines across geographically dispersed populations. Mexico and Brazil show increasing demand for immuno-oncology and targeted drugs, supported by expanding private oncology care, tertiary cancer centers, and public health investments, although molecular diagnostic coverage remains variable.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are central to clinical research, guideline-led treatment adoption, and health technology assessment of novel gastric cancer drugs. Germany and France maintain strong specialist oncology networks, the United Kingdom emphasizes evidence-based access and national treatment guidance, while Italy and Spain combine academic oncology activity with structured regional cancer care. Russia remains an important patient population but faces variability in access to innovative therapies, diagnostic infrastructure, and regional oncology resources.

China, India, Japan, Australia, and South Korea are pivotal Asia-Pacific markets for gastric cancer therapeutics. China combines large patient volumes with expanding domestic oncology innovation and increasing biomarker testing capacity, while India offers substantial clinical scale but continues to face access, affordability, and pathology infrastructure challenges. Japan and South Korea have advanced screening systems, high clinical expertise, and strong adoption of evidence-based gastric cancer treatment, making them influential in regional standards of care. Australia maintains strong precision oncology capabilities, clinical trial networks, and structured reimbursement assessment for innovative cancer medicines.

Actionable Recommendations for Gastric Cancer Drug Industry Leaders

Industry leaders should prioritize biomarker-integrated development strategies, ensuring that HER2, PD-L1 combined positive score, MSI-H/dMMR, EBV status, and CLDN18.2 testing are embedded in trial design, launch planning, physician education, and patient identification workflows. Partnerships with diagnostic providers, pathology networks, and cancer centers can reduce treatment delays, improve eligible patient detection, and strengthen confidence in biomarker-directed gastric cancer drugs.

Organizations should also expand real-world evidence programs to demonstrate survival, tolerability, treatment sequencing value, quality-of-life outcomes, and cost-effectiveness across diverse healthcare settings. A differentiated access strategy is essential, with value-based evidence packages for mature markets and tiered pricing, local partnerships, diagnostic capacity-building, and patient support initiatives for emerging regions with high gastric cancer burden. Leaders should further invest in AI-enabled trial operations, regional clinical trial diversity, and post-approval evidence generation to sustain competitive positioning.

Research Methodology for Gastric Cancer Drugs Analysis

This executive summary is developed from verified secondary research, including publicly available oncology guidelines, regulatory announcements, peer-reviewed clinical trial data, cancer epidemiology databases, cancer registry publications, and government health sources. Epidemiological framing reflects global cancer statistics such as GLOBOCAN 2022 and disease-burden reporting from recognized public health organizations.

Market interpretation applies triangulation across clinical evidence, regulatory approvals, biomarker trends, regional treatment access, cancer screening practices, reimbursement frameworks, and healthcare infrastructure. The methodology emphasizes data-backed insights, cross-validation of therapeutic trends, and qualitative assessment of commercialization dynamics in the gastric cancer drugs landscape, while avoiding market estimation, market sizing, market share, and forecasting.

Conclusion: Future Direction for Gastric Cancer Drugs

The gastric cancer drugs landscape is entering a more precise and competitive phase as immunotherapy, HER2-directed therapy, anti-angiogenic therapy, and CLDN18.2-targeted treatment reshape standards of care. High global mortality underscores the need for earlier diagnosis, broader biomarker testing, improved access to molecular pathology, and more durable treatment responses in both advanced and localized disease settings.

Future leadership will depend on clinical differentiation, diagnostic integration, regional access execution, and evidence generation across diverse patient populations. Stakeholders that align innovation with affordability, real-world outcomes, companion diagnostic readiness, and local cancer-control priorities will be better positioned to improve treatment adoption and patient outcomes in gastric cancer therapeutics.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Gastric Cancer Drugs Market, by Therapeutic Class

• 7.1. Chemotherapy
  • 7.1.1. Fluoropyrimidines
  • 7.1.2. Platinum-Based Agents
  • 7.1.3. Taxanes
• 7.2. Immune Checkpoint Inhibitors
  • 7.2.1. PD-1 Inhibitors
  • 7.2.2. PD-L1 Inhibitors
• 7.3. Targeted Therapy
  • 7.3.1. HER2 Inhibitors
  • 7.3.2. VEGF Inhibitors

8. Gastric Cancer Drugs Market, by Treatment Line

• 8.1. First Line
• 8.2. Second Line
• 8.3. Third Line Or Later

9. Gastric Cancer Drugs Market, by Route Of Administration

• 9.1. Intravenous
• 9.2. Oral
• 9.3. Subcutaneous

10. Gastric Cancer Drugs Market, by Dosage Form

• 10.1. Capsules
• 10.2. Lyophilized Powder
• 10.3. Injectable Solution
• 10.4. Tablets

11. Gastric Cancer Drugs Market, by Therapy Type

• 11.1. Combination Therapy
• 11.2. Monotherapy

12. Gastric Cancer Drugs Market, by Distribution Channel

• 12.1. Hospital Pharmacies
• 12.2. Retail Pharmacies

13. Gastric Cancer Drugs Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Gastric Cancer Drugs Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Gastric Cancer Drugs Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Amgen Inc.
• 17.2. Astellas Pharma Inc.
• 17.3. AstraZeneca PLC
• 17.4. Bayer AG
• 17.5. BeOne Medicines, Ltd.
• 17.6. Boehringer Ingelheim International GmbH
• 17.7. Bristol-Myers Squibb Company
• 17.8. Cipla Limited
• 17.9. Eli Lilly and Company
• 17.10. F. Hofmann-La Roche Ltd.
• 17.11. Gilead Sciences, Inc.
• 17.12. GlaxoSmithKline PLC
• 17.13. Incyte Corporation
• 17.14. Ipsen Pharma
• 17.15. LES LABORATOIRES SERVIER
• 17.16. Merck & Co., Inc.
• 17.17. Novartis AG
• 17.18. Ono Pharmaceutical
• 17.19. Pfizer, Inc.
• 17.20. Prestige Biopharma
• 17.21. Sanofi SA
• 17.22. Sumitomo Pharma Co., Ltd.
• 17.23. Sun Pharmaceuticals Limited
• 17.24. Taiho Pharmaceutical Co., Ltd.
• 17.25. Takeda Pharmaceutical Company Limited
• 17.26. Teva Pharmaceutical Industries Ltd.